Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_27_2275 - Salvage brachytherapy in prostate cancer after radiation failure: HDR vs LDR

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Salvage brachytherapy in prostate cancer after radiation failure: HDR vs LDR
I. Henriquez Lopez1, C. González2, J. Olivera Vegas3, C. Gutierrez4, M. D. L. A. Cabeza Rodriguez5, J. Valero Albarrán6, S. Rodriguez Villalba7, A. Hervas8, G. Sancho Pardo9, A. Alvarez Gonzalez10, A. Zapatero11, and P. Cuesta-Alvaro12; 1Hospital Universitario Sant Joan, Reus, Tarragona, Spain, 2Complutense University, Madrid, Spain, 3Fundacion Jimenez Diaz, Madrid, Spain, 4Instituto Catalan Oncologia (ICO), Barcelona, Spain, 5HU Doce de Octubre, Madrid, Spain, 6Hospital Universitary HM Sanchinarro, Madrid, Spain, 7Hospital Clinica Benidorm, Benidorm, Spain, 8Hospital Universitario Ramon y Cajal, Madrid, Spain, 9Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Gregorio Marañon, Madrid, Spain, 11Hospital Universitario de La Princesa, Madrid, Spain, 12Computer Services. Department of Statistical. Universidad Complutense, Madrid, Spain

Purpose/Objective(s): To evaluate efficacy and toxicity of HDR and LDR brachytherapy (BT) as salvage modalities in prostate cancer (PCa) patients after primary radiotherapy failure.

Materials/Methods: Between 2001 and 2016, 126 patients were treated with BT as salvage local treatment, 47 with LDR and 79 with HDR. All patients had biopsy proven local relapse. 31 patients (25%) received androgen deprivation therapy at the time of BT. Post-salvage BT progression and cause-specific-mortality of both treatment modalities (LDR and HDR) were analyzed. Toxicity was evaluated by RTOG scale.

Results: Median follow-up was 52 months (4-186) from BT. In 23 patients, HDR was used as a salvage modality because LDR-BT was already used as initial treatment. 39 patients progressed after salvage BT, 15 (32%) in LDR and 24 (30%) in HDR group. The 5-yr cause-specific survival was 97% with LDR and 94% with HDR (p=ns). On multivariate analysis, factors associated to progression were initial score Gleason ≥7 (p=0.02), time to BF from initial RT < 30 months (p=0.00) and nadir PSA post-salvage BT (p=0.00). 14 patients had urethral stenosis, 18 urinary incontinence and 13 haematuria. Grade ≥3 toxicity was observed in 22%.

Conclusion: Salvage BT in PCa patients who have local failure after radiation therapy can achieve local control > 70% with an adequate toxicity profile. There were not significant differences observed neither in efficacy nor in toxicity between HDR and LDR modalities.

Author Disclosure: I. Henriquez Lopez: None. C. González: None. J. Olivera Vegas: None. M. Cabeza Rodriguez: None. S. Rodriguez Villalba: None. A. Hervas: None. A. Zapatero: Travel Expenses; Janssen.

Ivan Henriquez Lopez, PhD

Biography:
Name: Ivan Henriquez Lopez

Degrees: Radiation Oncologist and Medical Oncologist
Medical Staff
Work place : University Hospital Sant Joan, Reus
Pere Virgili Health Research Institute ( IISPV ). Rovira i Virgili University , Tarragona
Consultant of Radiation Oncology Medical institue (IMOR), Barcelona, spain

Summary CV

Merit schoolars
Speciality of Medical Oncology at University Clinic of Navarra, Spain
1987-1990
Speciality of Radiation Oncology , Hospital Clinic, Barcelona, Spain
1994-1997
Doctor of Medicine by University of Navarra, 1991 (PhD)
Ex –secretary of Catalan - Balearic Oncology Society 2007 – 2010
Coordinator of Uro-oncology Radiation Spanish Group (URONCOR) at Spanish Radiation Oncology Society (SEOR)
Tutorial Coordinator of trainning residents in Radiation Oncology Department at University Hospital of Sant Joan, Reus



Teaching activity :
Associate Professor at Medicine Faculty at University of Reus
Professor in Radiotherapy for Technicians, Tarragona
Proffesor of Spanish Radiation Oncology Society (SEOR-EEOR) in the Master of Clinical Oncology
Invited proffesor to Scientific national and international Radiation Oncology meetings for more than 21 years

Scientific merits :
More than 180 scientific works presented at the Radiation Scientific Community ( Congress )

Scientific Publications :
A total of 48 scientific papers published on national and international Oncology Journals

Publications Books
Editor-in-chief of Prostate Cancer Book title “Controversies in Prostate Cancer”
Co-Editor-in-chief with Proffesor Mark Roach (UCLA University, USA) of Prostate Cancer Book. " Controversies in Prostate Cancer 2".
Co-Editor-in-chief with Proffesor Alberto Bossi (Gustave Roussy, Paris, France) of Prostate Cancer Book. " Controversies in Prostate Cancer 3".
First author and co-authors of more than 21 chapters in Medical and Radiation oncology Books

Research Group
Member of Radiation Oncology Research Group at Pere Virgili Health Research Institute ( IISPV )
Principal investigator and head of research trials in ongoing Basic and Clinical Oncology

Presentation(s):

Send Email for Ivan Henriquez Lopez


Assets

SU_27_2275 - Salvage brachytherapy in prostate cancer after radiation failure: HDR vs LDR



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Salvage brachytherapy in prostate cancer after radiation failure: HDR vs LDR